Neoadjuvant letrozole and palbociclib in patients with HR-positive/HER2-negative early breast cancer and Oncotype DX Recurrence Score ≥18: DxCARTES study
The efficacy of neoadjuvant treatment with letrozole plus palbociclib does not seem to depend on pretreatment RS for patients with RS ≥18. However, around half of patients with HR-positive/HER2-negative early breast cancer with an RS 26-100 at baseline achieved molecular downstaging with this regimen.
Authors
- A Llombart-Cussac
- J. de la Haba
- Begoña Bermejo (ORCID: https://orcid.org/0000-0001-7773-5994)
- Meritxell Bellet (ORCID: https://orcid.org/0000-0001-8859-8307)
- M Sampayo-Cordero
- Miguel Gil‐Gil (ORCID: https://orcid.org/0000-0003-1380-2718)
- Ángel Guerrero‐Zotano (ORCID: https://orcid.org/0000-0003-0318-9120)
- Laura Calabuig
- Manuel Ruíz‐Borrego (ORCID: https://orcid.org/0000-0002-1181-5622)
- Jhudit Pérez‐Escuredo (ORCID: https://orcid.org/0009-0009-1691-1849)
- Selena Morales
- Javier Cortés (ORCID: https://orcid.org/0000-0001-7623-1583)
- Ángela Antón
- Pedro Sánchez‐Rovira (ORCID: https://orcid.org/0000-0003-2658-1467)
- Vicente Carañana
- Ander Urruticoechea (ORCID: https://orcid.org/0000-0003-0359-3641)
- Vanesa Quiroga (ORCID: https://orcid.org/0000-0002-7852-474X)
- E. Alba Conejo
- María Fernández (ORCID: https://orcid.org/0000-0002-4382-4726)
- J. M. Perez-Garcia (ORCID: https://orcid.org/0009-0004-2204-2014)
Institutions
- Fundación Instituto Valenciano de Oncología (ES)
- Institut Català d'Oncologia (ES)
- Hospital Universitario Miguel Servet (ES)
- Complejo Hospitalario de Jaén (ES)
- Hospital Arnau de Vilanova (ES)
- Hospital Universitario Reina Sofía (ES)
- Hospital Clínico Universitario Virgen de la Victoria (ES)
- Hospital Universitario Ramón y Cajal (ES)
- GEICAM – Spanish Breast Cancer Group (ES)
- Instituto de Investigación Biomédica de Málaga (ES)
Publication Details
- Journal
- ESMO Open
- Published
- 2024-09-30
- DOI
- https://doi.org/10.1016/j.esmoop.2024.103733
- Citations
- 3
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Pfizer
- Novartis
- Genomic Health